GlassScriptPhysician profile
Nathaniel Neal
NPI 1720006729
$32,743.75
in general payments reported to CMS, 2019-2025
49 companies · $3,502 in 2025
The $3,502 reported for 2025 was more than what 80% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,358 · 2020: $2,941 · 2021: $4,565 · 2022: $5,096 · 2023: $4,504 · 2024: $6,779 · 2025: $3,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $2,160 · Education: $154 · Travel and Lodging: $76.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,393.44 |
| Consulting Fee | $2,160.00 |
| Education | $153.99 |
| Travel and Lodging | $76.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $5,076.41 | 2019-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $4,782.61 | 2019-2025 | |
| Amgen INC. | $4,013.41 | 2019-2025 | Enbrel, Otezla, Evenity |
| Pfizer INC. | $2,260.17 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,810.03 | 2019-2025 | |
| Celgene Corporation | $1,664.36 | 2019 | |
| Ucb, INC. | $1,529.63 | 2020-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $1,462.40 | 2019-2025 | Taltz, Zepbound |
| Glaxosmithkline, LLC. | $1,370.63 | 2019-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $1,133.08 | 2021-2025 | Lupkynis |
| Radius Health, INC. | $1,015.11 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,003.62 | 2019-2025 | Ofev, Cyltezo |
| Astrazeneca Pharmaceuticals LP | $900.25 | 2021-2025 | Saphnelo, Flumist Quadrivalent, Evusheld |
| Horizon Therapeutics Plc | $898.61 | 2019-2023 | Krystexxa |
| Fresenius Kabi USA, LLC | $531.23 | 2023-2025 | Idacio |
Show all 45 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Neal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.